Serum interleukin-2 levels in a patient with focal segmental glomerulosclerosis. Relationship to clinical course and cyclosporin A therapy.
We describe a patient with steroid-resistant focal segmental glomerulosclerosis (FSGS) whose serum interleukin-2 (IL-2) levels were markedly elevated in association with disease activity. With cyclosporin A (CsA) treatment, the patient entered remission and serum IL-2 fell to undetectable levels. After cessation of CsA, the patient relapsed and the serum IL-2 levels were elevated again. Reinstitution of CsA therapy was followed by a partial remission and disappearance of detectable serum IL-2 levels.
Jordan
S C
SC
Pediatric Center, Cedars-Sinai Medical Center, Los Angeles, California 90048.
Querfeld
U
U
Toyoda
M
M
Prehn
J
J
D003524:Cyclosporins / Q000627:therapeutic use; D004351:Drug Resistance; D005921:Glomerulonephritis / Q000097:blood*; D005923:Glomerulosclerosis, Focal Segmental / Q000097:blood* / Q000188:drug therapy; D006801:Humans; D007223:Infant; D007376:Interleukin-2 / Q000097:blood*; D008297:Male; D009404:Nephrotic Syndrome / Q000097:blood / Q000188:drug therapy; D011239:Prednisolone / Q000627:therapeutic use; D013997:Time Factors
D003524:Cyclosporins; D007376:Interleukin-2; D011239:Prednisolone